Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
102,089,423
-
Total 13F shares
-
59,307,013
-
Share change
-
+16,062,410
-
Total reported value
-
$1,061,573,186
-
Put/Call ratio
-
51%
-
Price per share
-
$17.90
-
Number of holders
-
80
-
Value change
-
+$302,547,160
-
Number of buys
-
56
-
Number of sells
-
26
Institutional Holders of Day One Biopharmaceuticals, Inc. - COMMON STOCK (DAWN) as of Q2 2022
As of 30 Jun 2022,
Day One Biopharmaceuticals, Inc. - COMMON STOCK (DAWN) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,307,013 shares.
The largest 10 holders included
Canaan Partners XI LLC, Atlas Venture Life Science Advisors, LLC, RA CAPITAL MANAGEMENT, L.P., FMR LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, FRANKLIN RESOURCES INC, PRICE T ROWE ASSOCIATES INC /MD/, and BlackRock Inc..
This page lists
80
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.